Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple blood test could spot cancer early

NCT ID NCT06842615

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood test called PanTum Detect to see how well it can find early signs of cancer or pre-cancer. The test looks for certain markers in immune cells. Researchers will compare the blood test results with standard PET/CT scans in 134 adults—half with suspected or confirmed tumors, and half healthy volunteers. The goal is to see if the blood test is accurate enough to be used for early cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PanTum Detect blood test
What this could lead to
If successful, this blood test could offer a simpler, less invasive way to screen for multiple types of cancer or pre-cancer at an early stage.
What could go wrong
This is a small, early-phase study (134 people) focused on accuracy, not treatment. The test may not be sensitive or specific enough, and results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 134 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 88 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be eligible to participate in this trial, an individual must meet all the following criteria: Group A * Age 18-88 years at inclusion (Man, Woman) * Suspected or confirmed macroscopic solid pre-malignant or malignant lesion(s) * Availability of result of FDG PET/CT performed -30 to-15 days or up to +30 days from trial intervention and performed as a standard of care * Willingness to undergo trial intervention * Signed informed consent * Absence of any of exclusion criteria Group B * Age 18-88 years at inclusion (Man, Woman) * Considered as free of pre-malignant or malignant lesion(s) at the time of inclusion * Willingness to undergo trial intervention * Signed informed consent * Absence of any of exclusion criteria Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this trial: For Group A and B 1. Acute Illness, Organ Transplantation, Surgeries, and injuries are an exclusion criteria: e.g. bone fracture, deep cut (deeper 0.5 cm and/or larger than 1 cm), abrasion (greater than 5 cm in diameter), open wound, contusion, torn ligaments, blood in the stool, blood in the urine. After successful recovery the waiting period must be 8 weeks. 2. Medication: Any treatment or activity that could impact the immune system must be considered as an exclusion criteria.These includes. 1. Steroid-, chemo-, radio therapy in last 8 weeks 2. Immunesuppression using following active ingredients; Methotrexate, Cyclosporine, Azathioprine, Tacrolimus, Mycophenolate, Rapamycin, Sirolimus, Mycophenolat-Mofetil in last 8 weeks. 3. Granulocyte-Macrophage Colony-Stimulating Factor (GM-SCF); Molgramostim, Sargramostim in last 8 weeks o Amygdalin (Vitamin B17) in last 4 weeks 4. Immune modulation using Corticosteroids, Glucocorticoids and Colchicine (Cortison/hydrocortisone \>5 mg/day, Budesonid \>5 mg/day) in last 4 weeks 5. Non-Steroidal anti-inflammatory drugs (NSAIDs) \& CGRP including in last 2 weeks. An occasional use of Ibuprofen, Paracetamol and Aspirin is not an exclusion criteria. 6. Antibiotics and Antifungals in last 2 weeks 3. Vaccination: any vaccination in last 4 weeks. 4. Infection: Acute Bacterial, Viral infection and Fungal infection in last 2 weeks. 5. Imaging Investigation using contrast medium in last 2 weeks. 6. Dialysis on the day of blood draw. 7. Genetic disorder such as thrombocytopenia may leads to rejection of test due to reduced amount of Blood Cells. For Group B only: 1\. Previous and Current Cancer: In case of previously diagnosed and successfully treated Tumour \& cancer, the PanTum Detect test should be done 5 years after the successful treatment \& cure. This applies to all kind of Tumour and Cancers. all currently ongoing cancer treatments and newly diagnosed cancer including ongoing diagnostic procedures are an exclusion criterion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macroscopic solid pre-malignant lesion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Nuclear Medicine

    RECRUITING

    Bratislava, Slovakia